Cargando…

Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study

Stereotactic ablative body radiation (SABR) delivers high rates of local control in early-stage non-small cell lung cancer (NSCLC); however, systemic immune effects are poorly understood. Here, we evaluate the early pathologic and immunologic effects of SABR. Blood/core-needle tumor biopsies were co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voong, Khinh Ranh, Illei, Peter B, Presson, Bradley, Singh, Dipika, Zeng, Zhen, Lanis, Mara, Hales, Russell K, Hu, Chen, Tran, Phuoc T, Georgiades, Christos, Lin, Cheng Ting, Thiboutout, Jeffrey, Brahmer, Julie R, Forde, Patrick M, Naidoo, Jarushka, Anagnostou, Valsamo, Smith, Kellie N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551924/ https://www.ncbi.nlm.nih.gov/pubmed/37793854 http://dx.doi.org/10.1136/jitc-2023-007188

Ejemplares similares

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Patient-reported outcome measures in definitive chemoradiation for non-small cell lung cancer
por: Voong, Khinh Ranh, et al.
Publicado: (2020)

Radiologic response of chemotherapy alone versus radiation and chemotherapy in the treatment of locally‐advanced or advanced thymic epithelial tumors
por: Chu, Robert F., et al.
Publicado: (2020)

Case Report: Hematologic Recovery Following Stereotactic Ablative Radiotherapy in a Patient With Early-Stage Non-Small Cell Lung Cancer and Paraneoplastic Myelofibrosis
por: Sloan, Lindsey, et al.
Publicado: (2022)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
por: Liang, Kai-li, et al.
Publicado: (2022)

DAART: a deep learning platform for deeply accelerated adaptive radiation therapy for lung cancer
por: Hooshangnejad, Hamed, et al.
Publicado: (2023)

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
por: Wills, Beatriz, et al.
Publicado: (2018)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
por: Reuss, Joshua E, et al.
Publicado: (2020)

Evaluating Proton Dose and Associated Range Uncertainty Using Daily Cone-Beam CT
por: Li, Heng, et al.
Publicado: (2022)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
por: Balaji, Aanika, et al.
Publicado: (2021)

A digital physician peer to automatically detect erroneous prescriptions in radiotherapy
por: Li, Qiongge, et al.
Publicado: (2022)

Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact
por: Hazell, Sarah Z., et al.
Publicado: (2020)

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
por: Rosner, Samuel, et al.
Publicado: (2023)

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
por: Scott, Susan C., et al.
Publicado: (2022)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis
por: Cappelli, Laura C, et al.
Publicado: (2022)

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management
por: Naidoo, Jarushka, et al.
Publicado: (2020)

CLRM-11 ALK TYROSINE KINASE INHIBITOR THERAPY AND BRAIN METASTASES IN NON-SMALL CELL LUNG CANCER: IMPACT ON TUMOR SIZE AND DISTRIBUTION
por: Kamson, David Olayinka, et al.
Publicado: (2023)

Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma
por: Voong, Khinh Ranh, et al.
Publicado: (2014)

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
por: Cluxton, Christopher, et al.
Publicado: (2023)

Computational simulation of the predicted dosimetric impact of adjuvant yttrium-90 PET/CT-guided percutaneous ablation following radioembolization
por: Pasciak, Alexander S., et al.
Publicado: (2016)

Derivation of CD8(+) T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis
por: Topper, Michael J., et al.
Publicado: (2023)

Liquid biopsies coming of age: biology, emerging technologies, and clinical translation- An introduction to the JITC expert opinion special review series on liquid biopsies
por: Stewart, Mark D., et al.
Publicado: (2023)

Immune-Related Adverse Events: A Case-Based Approach
por: Connolly, Caoilfhionn, et al.
Publicado: (2019)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Persistent mutation burden drives sustained anti-tumor immune responses
por: Niknafs, Noushin, et al.
Publicado: (2023)

Tracing the genetic fingerprints of tumour evolution: The pursuit of identifying mutations with differential weights within the overall tumour mutation burden and their role in therapeutic responses with immune checkpoint blockade
por: Niknafs, Noushin, et al.
Publicado: (2023)

Successful Treatment of Scar Pain with Scrambler Therapy
por: Yarchoan, Mark, et al.
Publicado: (2019)

From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023)

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
por: Belchis, Deborah A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fkom8fuub7j5bbnn80jn0gsje5